Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
28/04/2025 12:42
April 28 (Reuters) - Redhill Biopharma Ltd 2RHy.F: REDHILL BIOPHARMA SECURES ALLOWANCE OF KEY CHINESE PATENT APPLICATION FOR PROPRIETARY COVID-19 TREATMENT, RHB-107 Source text: ID:nPnc752Xba Further company coverage: [2RHy.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Heidelberg Pharma AG
See all newsBrief: Heidelberg Pharma And Huadong Medicine Receive Nmpa Approval For Hdp-101 Trial In China
Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments
Brief: Heidelberg Pharma Says Co. And Healthcare Royalty Announce Amendment To Existing Royalty Agreement
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: Heidelberg Pharma Amends Royalty Financing With Healthcare Royalty